Gyriki Despoina, Nikolaidis Christos, Stavropoulou Elisavet, Bezirtzoglou Ioanna, Tsigalou Christina, Vradelis Stergios, Bezirtzoglou Eugenia
Master Program in "Food, Nutrition and Microbiome", Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Internal Medicine Department, Vostaneio-General Hospital of Mytilene, 81100 Mytilene, Greece.
J Pers Med. 2024 May 11;14(5):507. doi: 10.3390/jpm14050507.
Inflammatory Bowel Disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic and relapsing inflammatory condition of the intestine that significantly impairs quality of life and imposes a heavy burden on healthcare systems globally. While the exact etiology of IBD is unclear, it is influenced by genetic, environmental, immunological, and microbial factors. Recent advances highlight the gut microbiome's pivotal role in IBD pathogenesis. The microbial dysbiosis characteristic of IBD, marked by a decline in beneficial bacteria and an increase in pathogenic microbes, suggests a profound connection between microbial imbalance and disease mechanisms. This review explores diagnostic approaches to IBD that integrate clinical assessment with advanced microbiological analyses, highlighting the potential of microbiome profiling as a non-invasive diagnostic tool. In addition, it evaluates conventional and emerging treatments and discusses microbiome-targeted intervention prospects, such as probiotics, symbiotics, and faecal microbiota transplantation. The necessity for future research to establish their efficacy and safety is emphasised.
炎症性肠病(IBD)包括克罗恩病(CD)和溃疡性结肠炎(UC),是一种肠道慢性复发性炎症性疾病,严重影响生活质量,给全球医疗系统带来沉重负担。虽然IBD的确切病因尚不清楚,但它受遗传、环境、免疫和微生物因素影响。最近的进展突出了肠道微生物群在IBD发病机制中的关键作用。IBD的微生物失调特征是有益菌减少和致病微生物增加,这表明微生物失衡与疾病机制之间存在着深刻联系。本综述探讨了将临床评估与先进微生物学分析相结合的IBD诊断方法,强调了微生物群分析作为一种非侵入性诊断工具的潜力。此外,它评估了传统和新兴治疗方法,并讨论了针对微生物群的干预前景,如益生菌、共生菌和粪便微生物群移植。强调了未来研究确定其疗效和安全性的必要性。